表位肽给药虽增强抗原特异性CD4 T细胞活化但抗分枝杆菌疗效有限
研究在小鼠结核感染模型中系统给予表位肽,发现其能选择性活化特异性T细胞、装载MHC II类分子于肺巨噬细胞和树突状细胞并活化肺实质CD4 T细胞,但抗分枝杆菌活性很小;进一步显示肺病灶内CD4 T细胞与感染细胞距离较远。
要点
- 系统给予表位肽可选择性活化针对该表位肽的T细胞。
- 表位肽给药使肺巨噬细胞和树突状细胞装载MHC II类分子并活化肺实质CD4 T细胞。
- 表位肽给药抗分枝杆菌活性很小,肺病灶CD4 T细胞与感染细胞距离较远。
核心结论
- 系统给予表位肽虽能活化CD4 T细胞,但抗分枝杆菌活性很小,CD4 T细胞定位及与感染细胞的直接相互作用可能是结核免疫的限制因素。
研究设计与样本
- 在感染结核分枝杆菌的小鼠中检查系统给予表位肽以活化预先存在T细胞的效用。
主要发现
- 系统肽给药选择性活化针对该表位肽的特异性T细胞。
- 系统肽给药使肺巨噬细胞和树突状细胞装载主要组织相容性复合体II类分子。
- 系统肽给药活化肺实质中的CD4 T细胞。
- 系统肽给药抗分枝杆菌活性很小。
- 肺病灶中的CD4 T细胞与感染细胞距离较远。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infection with Mycobacterium tuberculosis is associated with inconsistent and incomplete elimination of the bacteria, despite development of antigen-specific T-cell responses. One mechanism used by M tuberculosis is to limit availability of antigen for activation of CD4 T cells. METHODS: We examined the utility of systemic administration of epitope peptides to activate pre-existing T cells in mice infected with M tuberculosis. RESULTS: We found that systemic peptide administration (1) selectively activates T cells specific for the epitope peptide, (2) loads major histocompatibility complex class II on lung macrophages and dendritic cells, (3) activates CD4 T cells in the lung parenchyma, (4) and has little antimycobacterial activity. CONCLUSIONS: Further studies revealed that CD4 T cells in lung lesions are distant from the infected cells, suggesting that, even if they can be activated, the positioning of CD4 T cells and their direct interactions with infected cells may be limiting determinants of immunity in tuberculosis.
引用
- Ernst JD, Cornelius A, Desvignes L, et al. Limited Antimycobacterial Efficacy of Epitope Peptide Administration Despite Enhanced Antigen-Specific CD4 T-Cell Activation. J Infect Dis. 2018. PMID: 29548008. doi:10.1093/infdis/jiy142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。